A5067192900- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Urological Disorders and Treatments
- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Urologic and reproductive health conditions
- Nutrition and Health in Aging
- Renal cell carcinoma treatment
- Multiple and Secondary Primary Cancers
- Nutritional Studies and Diet
University of Turin
2021
Background and objectiveIntermediate-risk (IR) non–muscle-invasive bladder cancer (NMIBC) encompasses a broad spectrum of disease, with heterogeneous outcomes in terms disease recurrence progression. The International Bladder Cancer Group (IBCG) recently proposed an updated scoring model for IR substratification that is based on five key risk factors. Our aim was to provide clinical validation the IBCG system NMIBC.MethodsThis international multicenter retrospective study. Patients diagnosed...
BackgroundHigh-level evidence supporting the role of repeat transurethral resection (reTUR) in non–muscle-invasive bladder cancer (NMIBC) is lacking. A randomized controlled trial (RCT) assessing whether immediate reTUR has an impact on patient prognosis essential. However, since such a RCT will require enrollment high number patients, preliminary feasibility study appropriate.ObjectiveTo assess investigating + adjuvant bacillus Calmette-Guérin (BCG) versus upfront induction BCG after...
Skeletal muscle loss (sarcopenia) has been linked to cancer cachexia and can predict survival in several tumors, including advanced genitourinary malignancies.To investigate the predictive prognostic role of sarcopenia patients with T1 high grade (HG) non-muscle invasive bladder (NMIBC) treated adjuvant intravesical Bacillus Calmette-Guerin (BCG).Oncological outcomes were evaluated for 185 HG NMIBC BCG at two European referral centers. Sarcopenia, identified from computed tomography scans...
To evaluate the premalignant potential of high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical small acinar proliferation (ASAP).Patients diagnosed with monofocal HGPIN (mHGPIN), widespread (≥4 cores, wHGPIN) and/or ASAP who underwent at least one rebiopsy during their follow-up, were enrolled. All enrollment biopsies central pathologic revision. Risks for PCa estimated using Fine Gray method competing risk.Pathologic revision changed original diagnosis in 32.3% cases. Among...
You have accessJournal of UrologyBladder Cancer: Upper Tract Transitional Cell Carcinoma II (MP38)1 May 2024MP38-01 ONCOLOGICAL OUTCOMES AND PREOPERATIVE PREDICTORS OF DISEASE RECURRENCE IN UPPER TRACT UROTHELIAL CARCINOMA PATIENTS TREATED WITH DISTAL URETERECTOMY: RESULTS FROM A LARGE NATIONAL COHORT Matteo Rosazza, Francesco Soria, Simone Livoti, Daniele Dutto, Fulvia Colucci, Elisa De Lorenzis, Nazario Foschi, Guglielmo Mantica, Francesca Ambrosini, Riccardo Campi, Sergio Serni, Luisa...
You have accessJournal of UrologyBladder Cancer: Epidemiology & Evaluation II (MP35)1 May 2024MP35-11 LONG-TERM ONCOLOGICAL OUTCOMES OF DE NOVO BLADDER CANCER IN KIDNEY TRANSPLANT RECIPIENTS: RESULTS FROM A LARGE MULTICENTER INTERNATIONAL COHORT Simone Livoti, Francesco Soria, Matteo Rosazza, Daniele Dutto, Fulvia Colucci, David D'Andrea, Ekaterina Laukhtina, Jeremy Teoh, Gautier Marcq, Denis Séguier, Renate Pichler, Felizian Lackner, Robin Martin, Thierry Roumeguere, Albisinni, Benoit...
You have accessJournal of UrologyBladder Cancer: Non-invasive II (PD30)1 May 2024PD30-06 PHOTODYNAMIC DIAGNOSIS (PDD) DIRECTED BIOPSIES VS WHITE LIGHT BLADDER MAPPING IN PATIENTS WITH POSITIVE CYTOLOGY AND NEGATIVE PREOPERATIVE WORKUP: AN INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY Fulvia Colucci, Francesco Soria, Simone Livoti, Matteo Rosazza, Daniele Dutto, Gautier Marcq, Edouard Jarry, Laura Mertens, Marco Moschini, Mario Deangelis, Mattia Longoni, Rodolfo Hurle, Stefano Mancon, Renate...